Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Mar;88(3):106120.
doi: 10.1016/j.jinf.2024.106120. Epub 2024 Feb 16.

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Maya Hites  1 , Clément R Massonnaud  2 , Eva Larranaga Lapique  3 , Drifa Belhadi  2 , Simon Jamard  4 , François Goehringer  5 , François Danion  6 , Jean Reignier  7 , Nathalie de Castro  8 , Denis Garot  9 , Karine Lacombe  10 , Violaine Tolsma  11 , Emmanuel Faure  12 , Denis Malvy  13 , Thérèse Staub  14 , Johan Courjon  15 , France Cazenave-Roblot  16 , Anne Ma Dyrhol Riise  17 , Paul Leturnier  18 , Guillaume Martin-Blondel  19 , Claire Roger  20 , Karolina Akinosoglou  21 , Vincent Le Moing  22 , Lionel Piroth  23 , Pierre Sellier  24 , Xavier Lescure  25 , Marius Trøseid  26 , Philippe Clevenbergh  27 , Olav Dalgard  28 , Sébastien Gallien  29 , Marie Gousseff  30 , Paul Loubet  31 , Fanny Vardon-Bounes  32 , Clotilde Visée  33 , Leila Belkhir  34 , Élisabeth Botelho-Nevers  35 , André Cabié  36 , Anastasia Kotanidou  37 , Fanny Lanternier  38 , Elisabeth Rouveix-Nordon  39 , Susana Silva  40 , Guillaume Thiery  41 , Pascal Poignard  42 , Guislaine Carcelain  43 , Alpha Diallo  44 , Noémie Mercier  44 , Vida Terzic  44 , Maude Bouscambert-Duchamp  45 , Alexandre Gaymard  45 , Mary-Anne Trabaud  46 , Grégory Destras  47 , Laurence Josset  47 , Nicolas Billard  48 , Thi-Hong-Lien Han  48 , Jérémie Guedj  49 , Sandrine Couffin-Cadiergues  50 , Aline Dechanet  51 , Christelle Delmas  50 , Hélène Esperou  50 , Claire Fougerou-Leurent  52 , Soizic Le Mestre  44 , Anabelle Métois  51 , Marion Noret  53 , Isabelle Bally  54 , Sebastián Dergan-Dylon  54 , Sarah Tubiana  55 , Ouifiya Kalif  56 , Nathalie Bergaud  57 , Benjamin Leveau  57 , Joe Eustace  58 , Richard Greil  59 , Edit Hajdu  60 , Monika Halanova  61 , Jose-Artur Paiva  62 , Anna Piekarska  63 , Jesus Rodriguez Baño  64 , Kristian Tonby  17 , Milan Trojánek  65 , Sotirios Tsiodras  66 , Serhat Unal  67 , Charles Burdet  2 , Dominique Costagliola  68 , Yazdan Yazdanpanah  25 , Nathan Peiffer-Smadja  69 , France Mentré  2 , Florence Ader  70 ; DisCoVeRy study group  70
Affiliations
Free article
Comment

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Maya Hites et al. J Infect. 2024 Mar.
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest M.H. reports grants from The Belgian Center for Knowledge (KCE), the Fonds Erasme-COVID-Université Libre de Bruxelles and the EU-Horizon program, for the submitted work; and has received support for attending meetings from Pfizer; support for participation on an advisory board for therapeutics on COVID-19; and support for leadership for the Belgian guidelines on therapeutics for COVID-19 and acting as a treasurer for the Belgian Society of Clinical Microbiology and Infectious Diseases. R.G. reports consulting fees from Celgene, Novartis, Roche, Bristol Myers Squibb, Takeda, Abbvie, AstraZeneca, Janssen, Merck Sharp & Dohme, Merck, Gilead, and Daiichi Sankvo; lecture fees from Celgene, Roche, Merck, Takeda, AstraZeneca, Novartis, Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Sandoz, Abbvie, Gilead, and Daiichi Sankvo; support for attending meetings from Roche, Amgen, Janssen, AstraZeneca, Novartis, Merck Sharp & Dohme, Celgene, Gilead, Bristol Myers Squibb, Abbvie, and Daiichi Sankvo; participation in a Data Safety and Monitoring Board for Celgene, Novartis, Roche, Bristol Myers Squibb, Takeda, Abbvie, AstraZeneca, Janssen, Merck Sharp & Dohme, Merck, Gilead, and Daiichi Sankyo; research grants from Celgene, Roche, Merck, Takeda, AstraZeneca, Novartis, Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Sandoz, Abbvie, Gilead, and Daiichi Sankyo. J.-A.P. reports consulting fees from Pfizer, Merck Sharp & Dohme, and Janssen-Cilag; lecture fees from Pfizer; and support for attending meetings from Pfizer. D.C. reports grants and lecture fees from Janssen and lecture fees from Gilead, outside the submitted work. C.B. reports participation in a Data Safety and Monitoring Board for 4Living Biotech; and consulting fees from Da Volterra and Mylan Pharmaceuticals, outside the submitted work. F.M. reports grants and consulting fees from Da Volterra, grants from Sanofi, and consulting fees from Ipsen, outside the submitted work. All other authors declare no competing interests.

Comment on

References